V160-001-002: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

Project: Research project

Project Details

StatusFinished
Effective start/end date6/27/14 → 6/26/18

Funding

  • Merck Sharp and Cohme Corporation ( Award # ): $269,872.00